nach oben

Sleep and Breathing

Erschienen in:

27.05.2022 | Sleep Breathing Physiology and Disorders • Review

Prospect of thioredoxin as a possibly effective tool to combat OSAHS

verfasst von: Ye Pan, You Lu, Jie-dong Zhou, Cui-xue Wang, Jin-quan Wang, Atsushi Fukunaga, Junji Yodoi, Hai Tian

Erschienen in: Sleep and Breathing | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Obstructive sleep apnea–hypopnea syndrome (OSAHS) is characterized by recurrent upper airway disturbances during sleep leading to episodes of hypopnea or apnea, followed by hypoxemia and subsequent reoxygenation. It is believed that this reoxygenation/reperfusion stage leads to oxidative stress, which then leads to inflammation and cardiovascular diseases. The treatments of patient with OSAHS include surgical and non-surgical therapies with various side effects and common complaints. Therefore, it is important to develop a new, safe, and effective therapeutic treatment. As a small-molecule multifunctional protein, thioredoxin (TRX) has antioxidant and redox regulatory functions at the active site Cys-Gly-Pro. TRX prevents inflammation by suppressing the production of pro-inflammatory cytokines rather than suppressing the immune response.

Methods

We review the papers on the pathophysiological process of OSAHS and the antioxidative and anti-inflammatory effects of TRX.

Results

TRX may play a role in OSAHS by scavenging ROS, blocking the production of inflammatory cytokines, inhibiting the migration and activation of neutrophils, and controlling the activation of ROS-dependent inflammatory signals by regulating the redox state of intracellular target particles. Furthermore, TRX regulates the synthesis, stability, and activity of hypoxia-inducible factor 1 (HIF-1). TRX also has an inhibitory effect on endoplasmic reticulum- and mitochondria-induced apoptosis by regulating the expression of BAX, BCL2, p53, and ASK1.

Conclusion

Understanding the function of TRX may be useful for the treatment of OSAHS.

W T, J B, M LV, et al (2018) Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities. Eur Respir J 51

Wu ZH, Yang XP, Niu X et al (2019) The relationship between obstructive sleep apnea hypopnea syndrome and gastroesophageal reflux disease: a meta-analysis. Sleep Breath Schlaf Atmung 23:389–397PubMedCrossRef

Rivas M, Ratra A, Nugent K (2015) Obstructive sleep apnea and its effects on cardiovascular diseases: a narrative review. Anatolian J Cardiol 15:944–950CrossRef

Chan MTV, Wang CY, Seet E et al (2019) Association of unrecognized obstructive sleep apnea with postoperative cardiovascular events in patients undergoing major noncardiac surgery. JAMA 321:1788–1798PubMedPubMedCentralCrossRef

Mandavia R, Mehta N, Veer V (2020) Guidelines on the surgical management of sleep disorders: a systematic review. Laryngoscope 130:1070–1084PubMedCrossRef

Lavie L, Lavie P (2009) Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 33:1467–1484PubMedCrossRef

Ryan S, McNicholas WT (2008) Intermittent hypoxia and activation of inflammatory molecular pathways in OSAS. Arch Physiol Biochem 114:261–266PubMedCrossRef

Ryan S, Taylor CT, McNicholas WT (2005) Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112:2660–2667PubMedCrossRef

Mills PJ, Natarajan L, von Känel R et al (2009) Diurnal variability of C-reactive protein in obstructive sleep apnea. Sleep Breath Schlaf Atmung 13:415–420PubMedCrossRef

10.

Dyugovskaya L, Lavie P, Lavie L (2002) Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 165:934–939PubMedCrossRef

11.

Zhang D, Jia S, Wang H et al (2018) Effect of sustained hypoxia on autophagy of genioglossus muscle-derived stem cells. Med Sci Monit 24:2218–2224PubMedPubMedCentralCrossRef

12.

S S, S I, L F-S, et al (1991) Muscle fibre type and habitual snoring. Lancet (London, England) 337:597–599

13.

P H, DJ C, S W et al (2008) The surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. An assessment by the Australian and New Zealand intensive care society. Anaesthesia Intens Care 36:149–151

14.

Dyugovskaya L, Polyakov A, Lavie P et al (2008) Delayed neutrophil apoptosis in patients with sleep apnea. Am J Respir Crit Care Med 177:544–554PubMedCrossRef

15.

Hc L, Em W, Hs L et al (2017) Multilevel obstructive sleep apnea surgery. Adv Otorhinolaryngol 80:109–115

16.

Tahiri Y, Viezel-Mathieu A, Aldekhayel S et al (2014) The effectiveness of mandibular distraction in improving airway obstruction in the pediatric population. Plast Teconstruct Surg 133:352e–359eCrossRef

17.

Rossi DS, Romano M, Sweed AH et al (2019) Use of CAD-CAM technology to improve orthognathic surgery outcomes in patients with severe obstructive sleep apnoea syndrome. J Craniomaxillofac Surg 47:1331–1337PubMedCrossRef

18.

XH Y, HG L, X L et al (2012) Thioredoxin and impaired spatial learning and memory in the rats exposed to intermittent hypoxia. Chin Med J 125:3074–3080

19.

Suzuki YJ, Jain V, Park A-M et al (2006) Oxidative stress and oxidant signaling in obstructive sleep apnea and associated cardiovascular diseases. Free Radical Biol Med 40:1683–1692CrossRef

20.

AM P, YJ S (2007) Effects of intermittent hypoxia on oxidative stress-induced myocardial damage in mice. J Appl Physiol 102:1806–1814

21.

H T, Y M, A F et al (2013) Thioredoxin ameliorates cutaneous inflammation by regulating the epithelial production and release of pro-inflammatory cytokines. Front Immunol 4:269

22.

Q G, Y W, QY L et al (2013) Levels of thioredoxin are related to the severity of obstructive sleep apnea: based on oxidative stress concept. Sleep Breath Schlaf Atmung 17:311–316

23.

Matsuo Y, Yodoi J (2013) Extracellular thioredoxin: a therapeutic tool to combat inflammation. Cytokine Growth Factor Rev 24:345–353PubMedCrossRef

24.

H L, G W, J Z et al (2018) Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity. Oncol Rep 40:3447–3457

25.

Iwata Y, Okamoto M, Hoshino T et al (2010) Elevated levels of thioredoxin 1 in the lungs and sera of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia and cryptogenic organizing pneumonia. Int Med 49:2393–2400CrossRef

26.

Matsuzawa A (2017) Thioredoxin and redox signaling: roles of the thioredoxin system in control of cell fate. Arch Biochem Biophys 617:101–105PubMedCrossRef

27.

Powis G, Montfort WR (2001) Properties and biological activities of thioredoxins. Ann Rev Biophys Biomol Struct 30:421–455CrossRef

28.

HJ E, P M, R S (2015) Obstructive sleep apnea, oxidative stress, and cardiovascular disease: evidence from human studies. Oxidative Med Cell Longev 2015:608438

29.

Xf L, Xj Z, Yn L et al (2017) Estradiol regulates Txnip and prevents intermittent hypoxia-induced vascular injury. Sci Rep 7:10318CrossRef

30.

Guzy RD, Hoyos B, Robin E et al (2005) Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metabol 1:401–408CrossRef

31.

Paddenberg R, Ishaq B, Goldenberg A et al (2003) Essential role of complex II of the respiratory chain in hypoxia-induced ROS generation in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol 284:L710-719PubMedCrossRef

32.

Quinlan CL, Goncalves RLS, Hey-Mogensen M et al (2014) The 2-oxoacid dehydrogenase complexes in mitochondria can produce superoxide/hydrogen peroxide at much higher rates than complex I. J Biol Chem 289:8312–8325PubMedPubMedCentralCrossRef

33.

G P, S M, R S (2013) Reactive oxygen species production in peripheral blood neutrophils of obstructive sleep apnea patients. TheScientificWorldJournal 2013:421763

34.

Lavie L (2008) Intermittent hypoxia: the culprit of oxidative stress, vascular inflammation and dyslipidemia in obstructive sleep apnea. Exp Rev Respir Med 2:75–84CrossRef

35.

UC Y, V R, G D et al (2016) Oxidative stress in metabolic disorders: pathogenesis, prevention, and therapeutics. Oxidative Med Cell Longev 2016:9137629

36.

Bonello S, Zähringer C, BelAiba R et al (2007) Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 27:755–761PubMedCrossRef

37.

Nakamura H, Masutani H, Yodoi J (2006) Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer. Semin Cancer Biol 16:444–451PubMedCrossRef

38.

N Y, M Y, SI H et al (2019) Thioredoxin reductase gene expression and activity among human T-cell lymphotropic virus type 1-infected patients. J Med Virol 91:865–871

39.

Kanzok SM, Fechner A, Bauer H et al (2001) Substitution of the thioredoxin system for glutathione reductase in Drosophila melanogaster. Science (New York, NY) 291:643–646CrossRef

40.

Sw K, Hz C, Ms S et al (1998) Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 273:6297–6302CrossRef

41.

Zhou R, Yazdi AS, Menu P et al (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469:221–225PubMedCrossRef

42.

E Y, S M, Y M et al (2014) Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases. Front Immunol 4:514

43.

Hou Y, Wang Y, He Q et al (2018) Nrf2 inhibits NLRP3 inflammasome activation through regulating Trx1/TXNIP complex in cerebral ischemia reperfusion injury. Behav Brain Res 336:32–39PubMedCrossRef

44.

Zhou L, Ouyang R, Luo H et al (2018) Dysfunction of Nrf2-ARE signaling pathway: potential pathogenesis in the development of neurocognitive impairment in patients with moderate to severe obstructive sleep apnea-hypopnea syndrome. Oxid Med Cell Longev 2018:3529709PubMedPubMedCentralCrossRef

45.

Bindoli A, Rigobello M (2013) Principles in redox signaling: from chemistry to functional significance. Antioxid Redox Signal 18:1557–1593PubMedCrossRef

46.

Kim G, Jeong H, Yoon H et al (2020) Anti-inflammatory mechanisms of suppressors of cytokine signaling target ROS via NRF-2/thioredoxin induction and inflammasome activation in macrophages. BMB Rep 53:640–645PubMedPubMedCentralCrossRef

47.

Tanito M, Masutani H, Kim Y et al (2005) Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. Invest Ophthalmol Vis Sci 46:979–987PubMedCrossRef

48.

Malhotra D, Thimmulappa R, Mercado N et al (2011) Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J Clin Investig 121:4289–4302PubMedPubMedCentralCrossRef

49.

Tedder TF, Steeber DA, Pizcueta P (1995) L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J Exp Med 181:2259–2264PubMedCrossRef

50.

Watanabe R, Nakamura H, Masutani H et al (2010) Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2. Pharmacol Ther 127:261–270PubMedCrossRef

51.

Htoo AK, Greenberg H, Tongia S et al (2006) Activation of nuclear factor κB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 10:43–50PubMedCrossRef

52.

Kheirandishgozal L, Gozal D (2019) Obstructive sleep apnea and inflammation: proof of concept based on two illustrative cytokines. Int J Mol Sci 20:459PubMedCrossRef

53.

Liu W, Nakamura H, Shioji K et al (2004) Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 110:1276–1283PubMedCrossRef

54.

Billiet L, Furman C, Larigauderie G et al (2005) Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages. J Biol Chem 280:40310–40318PubMedCrossRef

55.

Nakamura H, Herzenberg LA, Bai J et al (2001) Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci U S A 98:15143–15148PubMedPubMedCentralCrossRef

56.

K A, E N, N P, et al (2018) The role of vitamin D in obstructive sleep apnoea syndrome. Breathe (Sheffield, England) 14:206–215

57.

Ahmad Y, Sharma NK, Garg I et al (2013) An insight into the changes in human plasma proteome on adaptation to hypobaric hypoxia. PloS one 8:e67548PubMedPubMedCentralCrossRef

58.

Drechsel DA, Patel M (2010) Respiration-dependent H2O2 removal in brain mitochondria via the thioredoxin/peroxiredoxin system. J Biol Chem 285:27850–27858PubMedPubMedCentralCrossRef

59.

Yu A, Frid M, Shimoda L et al (1998) Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 275:L818-826PubMed

60.

Ivan M, Kondo K, Yang H et al (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (New York, NY) 292:464–468CrossRef

61.

Lu H, Samanta D, Xiang L et al (2015) Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A 112:E4600-4609PubMedPubMedCentralCrossRef

62.

Mc S (2006) Coming up for air: HIF-1 and mitochondrial oxygen consumption. Cell Metab 3:150–151CrossRef

63.

Naranjo-Suarez S, Carlson B, Tobe R et al (2013) Regulation of HIF-1α activity by overexpression of thioredoxin is independent of thioredoxin reductase status. Mol Cells 36:151–157PubMedPubMedCentralCrossRef

64.

Welsh S, Bellamy W, Briehl M et al (2002) The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Can Res 62:5089–5095

65.

Farrell M, Rogers L, Liu Y et al (2010) Thioredoxin-interacting protein inhibits hypoxia-inducible factor transcriptional activity. Free Radical Biol Med 49:1361–1367CrossRef

66.

Zhou J, Eleni C, Spyrou G et al (2008) The mitochondrial thioredoxin system regulates nitric oxide-induced HIF-1alpha protein. Free Radical Biol Med 44:91–98CrossRef

67.

Zhou J, Damdimopoulos AE, Spyrou G et al (2007) Thioredoxin 1 and thioredoxin 2 have opposed regulatory functions on hypoxia-inducible factor-1α. J Biol Chem 282:7482–7490PubMedCrossRef

68.

Wang W, Huang L, Hu Y et al (2020) Neuroprotective effects of notoginsenoside R1 by upregulating Trx-1 on acrylamide-induced neurotoxicity in PC12. Hum Exp Toxicol 39:797–807PubMedCrossRef

69.

Song W, Chang W-L, Shan D et al (2020) Intermittent hypoxia impairs trophoblast cell viability by triggering the endoplasmic reticulum stress pathway. Reprod Sci 27:477–487PubMedCrossRef

70.

Tang L, Ren X, Han Y et al (2020) Sulforaphane attenuates apoptosis of hippocampal neurons induced by high glucose via regulating endoplasmic reticulum. Neurochem Int 136:104728PubMedCrossRef

71.

Zhou X, Tang S, Hu K et al (2018) DL-Propargylglycine protects against myocardial injury induced by chronic intermittent hypoxia through inhibition of endoplasmic reticulum stress. Sleep Breath Schlaf Atmung 22:853–863PubMedCrossRef

72.

Yang L, Guo N, Fan W et al (2020) Thioredoxin-1 blocks methamphetamine-induced injury in brain through inhibiting endoplasmic reticulum and mitochondria-mediated apoptosis in mice. Neurotoxicology 78:163–169PubMedCrossRef

73.

Mukherjee S, Lekli I, Ray D et al (2010) Comparison of the protective effects of steamed and cooked broccolis on ischaemia-reperfusion-induced cardiac injury. Br J Nutr 103:815–823PubMedCrossRef

74.

N A-K, F F, F A-S et al (2019) The thioredoxin system is regulated by the ASK-1/JNK/p38/Survivin pathway during germ cell Apoptosis. Molecules (Basel, Switzerland) 24

75.

Ishaq M, Kumar S, Varinli H et al (2014) Atmospheric gas plasma-induced ROS production activates TNF-ASK1 pathway for the induction of melanoma cancer cell apoptosis. Mol Biol Cell 25:1523–1531PubMedPubMedCentralCrossRef

76.

Takeda K, Matsuzawa A, Nishitoh H et al (2004) Involvement of ASK1 in Ca2+-induced p38 MAP kinase activation. EMBO Rep 5:161–166PubMedPubMedCentralCrossRef

77.

Matsuzawa A, Saegusa K, Noguchi T et al (2005) ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 6:587–592PubMedCrossRef

78.

Ren X, Lu H, Wang N et al (2017) Thioredoxin is implicated in the anti-apoptotic effects of grape seed proanthocyanidin extract during hyperglycemia. Mol Med Rep 16:7731–7737PubMedCrossRef

79.

Branco V, Coppo L, Solá S et al (2017) Impaired cross-talk between the thioredoxin and glutathione systems is related to ASK-1 mediated apoptosis in neuronal cells exposed to mercury. Redox Biol 13:278–287PubMedPubMedCentralCrossRef

80.

M S, H N, M F et al (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17:2596–2606

81.

Sheng L, Jiao B, Shao L et al (2013) Probucol inhibits hydrogen peroxide to induce apoptosis of vascular smooth muscle cells. Mol Med Rep 7:1185–1190PubMedCrossRef

82.

Al-Gayyar MMH, Abdelsaid MA, Matragoon S et al (2011) Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity. Br J Pharmacol 164:170–180PubMedPubMedCentralCrossRef

83.

HM E and NJ D (2004) Sleep. 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. Thorax 59:618–622

84.

WT M, MR B, MR B (2007) Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29:156–178

85.

Lavie L, Lavie P (2012) CrossTalk opposing view: Most cardiovascular diseases in sleep apnoea are not caused by sympathetic activation. The Journal of physiology 590:2817–2819; discussion 2821PubMedPubMedCentralCrossRef

86.

Kohler M, Stradling JR (2012) CrossTalk proposal: Most of the cardiovascular consequences of OSA are due to increased sympathetic activity. J Physiol 590:2813–2815; discussion 2823PubMedPubMedCentralCrossRef

Titel: Prospect of thioredoxin as a possibly effective tool to combat OSAHS
verfasst von: Ye Pan
You Lu
Jie-dong Zhou
Cui-xue Wang
Jin-quan Wang
Atsushi Fukunaga
Junji Yodoi
Hai Tian
Publikationsdatum: 27.05.2022
Verlag: Springer International Publishing
Erschienen in: Sleep and Breathing / Ausgabe 2/2023
Print ISSN: 1520-9512
Elektronische ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-022-02640-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Prospect of thioredoxin as a possibly effective tool to combat OSAHS